COVID-19 Vaccine Effectiveness by Product and Timing in New York State
COVID-19 Vaccine Effectiveness by Product and Timing in New York State
复制标题
纽约州按产品和时间划分的 COVID-19 疫苗有效性
DOI：
--
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
H. Zucker
中科院分区：
文献类型：
--
作者：
E. Rosenberg;Vajeera Dorabawila;D. Easton;U. Bauer;Jessica Kumar;Rebecca Hoen;D. Hoefer;Meng Wu;E. Lutterloh;MaryBeth Conroy;Danielle Greene;H. Zucker
背景：关于美国食品和药物管理局目前授权的3种产品的新冠肺炎疫苗有效性(VE)的美国人群数据有限。VE的下降是否由于免疫力减弱、Delta变异或其他原因而存在争议。方法：我们对8,834,604名纽约成年人进行了一项前瞻性研究，通过连接全州测试、医院和疫苗登记数据库，将按产品、年龄和完全接种的月份定义的疫苗队列与特定年龄的未接种队列进行比较。VE是从2021年5月1日实验室确认的新冠肺炎病例(截至9月3日的每周生命表危险率)和住院(截至8月31日的月度发病率)估计的。结果：共发生155,092例新冠肺炎病例，14,862例住院。在年龄、产品和时间队列中，估计的VE病例同时下降，从5月1日开始的高水平(1.8%Delta变异率)，到7月10日左右的最低点(85.3%Delta)，此后变化有限(>；95%Delta)。辉瑞生物科技的降幅最大(18-49年、50年和[≥]65年分别为-24.6%、-19.1%、-14.1%)，莫德纳(分别为-18.0%、-11.6%、-9.0%)和杨森(分别为-19.2%、-10.8%、-10.9%)类似。成人住院18-年的VE在队列中为86%，无时间趋势。在[≥]65岁的人群中，从5月到8月，辉瑞-生物科技(95.0%至89.2%)和现代(97.2%至94.1%)的VE下降。Janssen的VE较低，无趋势，在85.5%~82.8%之间。结论：病例VE的下降可能主要是由其他因素驱动的，而不是减弱。住院治疗的VE仍然很高，温和下降仅限于辉瑞-生物科技和莫德纳接受者[≥]65岁，支持有针对性的增强剂剂量建议。
Background: US population-based data on COVID-19 vaccine effectiveness (VE) for the 3 currently FDA- authorized products is limited. Whether declines in VE are due to waning immunity, the Delta variant, or other causes, is debated. Methods: We conducted a prospective study of 8,834,604 New York adults, comparing vaccine cohorts defined by product, age, and month of full-vaccination to age-specific unvaccinated cohorts, by linking statewide testing, hospital, and vaccine registry databases. VE was estimated from May 1, 2021 for incident laboratory-confirmed COVID-19 cases (weekly life-table hazard rates through September 3) and hospitalizations (monthly incidence rates through August 31). Results: 155,092 COVID-19 cases and 14,862 hospitalizations occurred. Estimated VE for cases declined contemporaneously across age, products, and time-cohorts, from high levels beginning May 1 (1.8% Delta variant prevalence), to a nadir around July 10 (85.3% Delta), with limited changes thereafter (>95% Delta). Decreases were greatest for Pfizer-BioNTech (-24.6%, -19.1%, -14.1% for 18-49, 50-64 years, and [≥]65 years, respectively), and similar for Moderna (-18.0%, -11.6%, -9.0%, respectively) and Janssen (-19.2%, -10.8, -10.9%, respectively). VE for hospitalization for adults 18-64 years was >86% across cohorts, without time trend. Among persons [≥]65 years, VE declined from May to August for Pfizer-BioNTech (95.0% to 89.2%) and Moderna (97.2% to 94.1%). VE was lower for Janssen, without trend, ranging 85.5%-82.8%. Conclusions: Declines in VE for cases may have been primarily driven by factors other than waning. VE for hospitalizations remained high, with modest declines limited to Pfizer-BioNTech and Moderna recipients [≥]65 years, supporting targeted booster dosing recommendations.